FDA Approves First-in-Class Combo Drug for Heart Failure
A pill combining valsartan and sacubitril has received first-in-class approval for heart failure under the Food and Drug Administration's priority review program. Entresto offers practitioners a new option for reducing risk of cardiovascular death and hospitalization in patients with NYHA class II-IV heart failure and reduced ejection fraction.
Source: Caring for the Ages - Category: Health Management Authors: Judith M. Orvos Source Type: news
More News: Cardiology | Cardiovascular | Diovan | Food and Drug Administration (FDA) | Health Management | Heart | Heart Failure